Manchester Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Manchester Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$44	–	1359
2026 Q1	$44	Hold	2	–	–	﹤0.01%	1305
2025 Q4	$44	Hold	2	–	–	﹤0.01%	1342
2025 Q3	$39	Sell	2 -235	-99%	-$4.19K	﹤0.01%	1286
2025 Q2	$4.05K	Hold	237	–	–	﹤0.01%	933
2025 Q1	$15.1K	Hold	237	–	–	﹤0.01%	767
2024 Q4	$28.8K	Buy	237 +110	+87%	+$13.5K	﹤0.01%	655
2024 Q3	$15.9K	Hold	127	–	–	﹤0.01%	722
2024 Q2	$20.1K	Buy	127 +125	+6,250%	+$16.1K	﹤0.01%	658
2024 Q1	$259	Hold	2	–	–	﹤0.01%	985
2023 Q4	$193	Sell	2 -1	-33%	-$96	﹤0.01%	976
2023 Q3	$364	Hold	3	–	–	﹤0.01%	924
2023 Q2	$344	Buy	+3	New	+$387	﹤0.01%	905
2021 Q1	–	Sell	-3	Closed	-$1K	–	773
2020 Q4	$1K	Buy	+3	New	+$445	﹤0.01%	699
2019 Q2	–	Sell	-570	Closed	-$68K	–	635
2019 Q1	$68K	Buy	+570	New	+$73.3K	0.01%	360
2014 Q2	–	Sell	-83	Closed	-$2K	–	1105
2014 Q1	$2K	Buy	+83	New	+$2.12K	﹤0.01%	967

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Manchester Capital Management's SRPT Position: Q2 2026 in Review

Manchester Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 2 shares — an estimated $44 sold.

Manchester Capital Management first reported a position in SRPT in Q1 2014 and held it in 15 quarters. The position peaked at $68K in Q1 2019. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Manchester Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
Manchester Capital Management sold 2 Sarepta Therapeutics shares in Q2 2026, an estimated $44.
Manchester Capital Management first reported a position in Sarepta Therapeutics in Q1 2014 and held it in 15 quarters.
Manchester Capital Management's Sarepta Therapeutics position peaked at $68K in Q1 2019.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.